Virtusa offers ICD-10 migration assessment

Jeff Byers | | Health Exec | Economics
Virtusa, a global IT services consulting company, has designed a customized migration assessment tool to help healthcare organizations determine the potential financial impact of transitioning from ICD-9 to ICD-10.

The conversion, which is mandated to take effect by October 2013, will multiply the number of available diagnosis and procedure codes from the current 24,000 to more than 155,000, according to the Westborough, Mass.-based company.

Virtusa’s complimentary, cloud-based financial modeling tools allow organizations to test various pricing scenarios and gauge the economic impact on different areas of operation, including:

  • Billing and payment schemes
  • Provider billing practices
  • Use of mapping tools
  • Medical policy coding
  • Coding errors
  • Fraud and abuse prevention

Jeff Byers

Related Content

Merck spends up to $2B to license new weight loss drug with potential heart benefits
Insulet wins $452M in lawsuit against rivals over medical device trade secrets
Medical device company cuts 70% of staff in push to meet Medtronic obligations
Cleerly’s momentum continues as AI specialists raise $106M
Operations manager, doctors charged in $70M imaging kickback scheme
Private-equity watchdog warns against nominating Marc Rowan as Treasury Secretary

Around the web

Cardiovascular Business
FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

AI in Healthcare
From Capitol Hill to a hospital near you? 5 federal recommendations for healthcare AI policy

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Cardiovascular Business
Merck spends up to $2B to license new weight loss drug with potential heart benefits

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.